Roche begins the year with solid sales growth in Q1, coming in marginally ahead of our expectation. Total sales grew by 4% (same as Q4 15 growth rate) at CER (+5% in CHF, thanks to a stronger dollar and Japanese yen benefit, offset to some extent by devaluations in Argentina as well as in Venezuela) to CHF12.4bn (vs our expectation of CHF12.2bn). NB All growth numbers at CER unless specified otherwise. The Pharmaceuticals division grew by 4% (to CHF9.8bn, +5% in CHF), while the Diagnostics in
24 Apr 2016
Strong Q1 with favourable forex impact
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q1 with favourable forex impact
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
24 Apr 2016 -
Author:
Kamla Singh -
Pages:
2
Roche begins the year with solid sales growth in Q1, coming in marginally ahead of our expectation. Total sales grew by 4% (same as Q4 15 growth rate) at CER (+5% in CHF, thanks to a stronger dollar and Japanese yen benefit, offset to some extent by devaluations in Argentina as well as in Venezuela) to CHF12.4bn (vs our expectation of CHF12.2bn). NB All growth numbers at CER unless specified otherwise. The Pharmaceuticals division grew by 4% (to CHF9.8bn, +5% in CHF), while the Diagnostics in